Table 3.
PR3-ANCA rises and relapses by subgroup
| Capture ELISA | Direct ELISA | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| Rise | 10 | CYC, RTX (3, 7) |
No rise | 5 | CYC, RTX (3, 2) |
Rise | 11 | CYC, RTX (5, 6) |
No rise | 4 | CYC, RTX (1, 3) |
|
|
|
|
|
|
|||||||||
|
Granulomatous Only (N = 15) |
Relapse | 8 | (3, 5) | Relapse | 5 | (3, 2) | Relapse | 9 | (5, 4) | Relapse | 4 | (1, 3) |
| Concurrent | 1 | (0, 1) | Concurrent | 1 | (1, 0) | |||||||
| ≤ 1 year | 4 | (1, 3) | ≤ 1 year | 5 | (2, 3) | |||||||
| > 1 year | 3 | (2, 1) | > 1 year | 3 | (2, 1) | |||||||
| No relapse | 2 | (0, 2) | No relapse | 0 | (0, 0) | No relapse | 2 | (0, 2) | No relapse | 0 | (0, 0) | |
|
| ||||||||||||
|
Renal Involvement (N = 60) |
Rise | 33 |
CYC, RTX (15, 18) |
No rise | 27 |
CYC, RTX (14, 13) |
Rise | 36 |
CYC, RTX (16, 20) |
No rise | 24 |
CYC, RTX (13, 11) |
|
|
|
|
|
|||||||||
| Relapse | 14 | (4, 10) | Relapse | 14 | (7, 7) | Relapse | 19 | (6, 13) | Relapse | 9 | (5, 4) | |
| Concurrent | 2 | (1, 1) | Concurrent | 5 | (0, 5) | |||||||
| ≤ 1 year | 10 | (3, 7) | ≤ 1 year | 13 | (6, 7) | |||||||
| > 1 year | 2 | (0, 2) | > 1 year | 1 | (0, 1) | |||||||
| No relapse | 19† | (11, 8) | No relapse | 13†† | (7, 6) | No relapse | 17* | (10, 7) | No relapse | 15** | (8, 7) | |
|
| ||||||||||||
|
Alveolar Hemorrhage (N = 24) |
Rise | 14 |
CYC, RTX (2, 12) |
No rise | 10 |
CYC, RTX (6, 4) |
Rise | 18 |
CYC, RTX (5, 13) |
No rise | 6 |
CYC, RTX (3, 3) |
|
|
|
|
|
|||||||||
| Relapse | 8 | (0, 8) | Relapse | 6 | (4, 2) | Relapse | 14 | (4, 10) | Relapse | 0 | (0, 0) | |
| Concurrent | 1 | (0, 1) | Concurrent | 3 | (0, 3) | |||||||
| ≤ 1 year | 6 | (0, 6) | ≤ 1 year | 10 | (4, 6) | |||||||
| > 1 year | 1 | (0, 1) | > 1 year | 1 | (0, 1) | |||||||
| No relapse | 6† | (2, 4) | No relapse | 4 | (2, 2) | No relapse | 4* | (1, 3) | No relapse | 6 | (3, 3) | |
|
| ||||||||||||
|
Rituximab (N = 50) |
Rise | 35 | No rise | 15 | Rise | 32 | No rise | 18 | ||||
|
|
|
|
|
|||||||||
| Relapse | 22 | Relapse | 9 | Relapse | 23 | Relapse | 8 | |||||
| Concurrent | 3 | Concurrent | 5 | |||||||||
| ≤ 1 year | 14 | ≤ 1 year | 14 | |||||||||
| > 1 year | 5 | > 1 year | 4 | |||||||||
| No relapse | 13† | No relapse | 6†† | No relapse | 9* | No relapse | 10** | |||||
|
| ||||||||||||
|
Cyclophosphamide (N = 43) |
Rise | 24 | No rise | 19 | Rise | 26 | No rise | 17 | ||||
|
|
|
|
|
|||||||||
| Relapse | 12 | Relapse | 12 | Relapse | 16 | Relapse | 8 | |||||
| Concurrent | 2 | Concurrent | 1 | |||||||||
| ≤ 1 year | 7 | ≤ 1 year | 11 | |||||||||
| > 1 year | 3 | > 1 year | 4 | |||||||||
| No relapse | 12† | No relapse | 7 | No relapse | 10* | No relapse | 9** | |||||
5 (2, 3) of the 19 had < 1 year of follow-up after PR3-ANCA rise
1 (0,1) of the 13 had < 1 year of follow-up after complete remission
4 (1, 3) of the 17 had < 1 year of follow-up after PR3-ANCA rise
2 (1, 1) of the 15 had < 1 year of follow-up after complete remission
1 (0, 1) of the 6 had < 1 year of follow-up after PR3-ANCA rise
1 (0, 1) of the 4 had < 1 year of follow-up after PR3-ANCA rise
4 of the 13 had < 1 year of follow-up after PR3-ANCA rise
1 of the 6 had < 1 year of follow-up after complete remission
3 of the 9 had < 1 year of follow-up after PR3-ANCA rise
1 of the 10 had < 1 year of follow-up after complete remission
2 of the 12 had < 1 year of follow-up after PR3-ANCA rise
1 of the 10 had < 1 year of follow-up after PR3-ANCA rise
1 of the 9 had < 1 year of follow-up after complete remission